Trial Outcomes & Findings for Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles (NCT NCT03878758)

NCT ID: NCT03878758

Last Updated: 2020-03-09

Results Overview

Injection pain as measured by a relative visual analog scale. This endpoint analyzes data for individual groups. User preference is assessed through a single question reported on a 150mm relative VAS scale with the BD Nano™ PRO pen needle Pen labeled at +75 mm and the Comparator pen needle labeled at -75mm. On this scale, zero represents no preference to either pen needle. Relative VAS scores range from -75mm to 75mm; positive scores reflect preference forBD Nano™ PRO and negative scores reflect preference for the comparator. Scores from each of the paired injections (308 pairs for all participants) were pooled and a mean was calculated. The two-sided 95% confidence interval was calcuated for the average relative rating. A linear model was used to adjust for the order effect. If the lower bound of the 95% CI is \> -10cm, non-inferiority could be concluded. If the lower bound of the 95% CI is \>0, superiority can also be concluded.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

158 participants

Primary outcome timeframe

Scores were collected immediately after each paired injection

Results posted on

2020-03-09

Participant Flow

Each subject received more than one treatment

Participant milestones

Participant milestones
Measure
All Study Participants
Subjects are to perform 6 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G or Artsana Insupen Extr3me 3.5mm x 34G or Simple Diagnostics Comfort EZ™ 4mm x 33G
Overall Study
STARTED
158
Overall Study
COMPLETED
154
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
All Study Participants
Subjects are to perform 6 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G or Artsana Insupen Extr3me 3.5mm x 34G or Simple Diagnostics Comfort EZ™ 4mm x 33G
Overall Study
Withdrawal by Subject
1
Overall Study
Protocol defined
2
Overall Study
Improper consent documentation
1

Baseline Characteristics

Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
All Study Participants
n=157 Participants
Subjects are to perform 6 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G or Artsana Insupen Extr3me 3.5mm x 34G or Simple Diagnostics Comfort EZ™ 4mm x 33G
Age, Continuous
56.2 years
STANDARD_DEVIATION 11.2 • n=5 Participants
Sex: Female, Male
Female
77 Participants
n=5 Participants
Sex: Female, Male
Male
80 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
12 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
145 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
2 Participants
n=5 Participants
Race (NIH/OMB)
Asian
23 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
12 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
16 Participants
n=5 Participants
Race (NIH/OMB)
White
88 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
16 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Scores were collected immediately after each paired injection

Population: Per-protocol population

Injection pain as measured by a relative visual analog scale. This endpoint analyzes data for individual groups. User preference is assessed through a single question reported on a 150mm relative VAS scale with the BD Nano™ PRO pen needle Pen labeled at +75 mm and the Comparator pen needle labeled at -75mm. On this scale, zero represents no preference to either pen needle. Relative VAS scores range from -75mm to 75mm; positive scores reflect preference forBD Nano™ PRO and negative scores reflect preference for the comparator. Scores from each of the paired injections (308 pairs for all participants) were pooled and a mean was calculated. The two-sided 95% confidence interval was calcuated for the average relative rating. A linear model was used to adjust for the order effect. If the lower bound of the 95% CI is \> -10cm, non-inferiority could be concluded. If the lower bound of the 95% CI is \>0, superiority can also be concluded.

Outcome measures

Outcome measures
Measure
BD Nano™ PRO Pen Needle vs 34G Artsana Insupen Extr3me
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2 BD Nano™ PRO: Insulin Pen needle 34G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs 33G Artsana Insupen Extr3me
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle 33G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs Simple Diagnostics Comfort EZ™
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle Simple Diagnostics Comfort EZ™: Insulin Pen Needle
Injection Site Pain for BD Nano PRO Needle Compared to Each of Three (3) Commercially Available Comparators
17.55 mm
Interval 11.43 to 23.67
17.39 mm
Interval 11.28 to 23.51
9.13 mm
Interval 3.01 to 15.25

SECONDARY outcome

Timeframe: Scores were collected immediately after each paired injection

Population: Per protocol population

Participants reported a visual score of needle bending. A score of at least 2, corresponding to \>10 degrees of bending, was considered an event of a bent needle. Scores from each injection (308 for each needle type) were pooled and a mean was calculated. The incidence of bent needle events in the BD Nano™ PRO and each competitor were compared and the mean difference reported with a 95% confidence interval.

Outcome measures

Outcome measures
Measure
BD Nano™ PRO Pen Needle vs 34G Artsana Insupen Extr3me
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2 BD Nano™ PRO: Insulin Pen needle 34G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs 33G Artsana Insupen Extr3me
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle 33G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs Simple Diagnostics Comfort EZ™
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle Simple Diagnostics Comfort EZ™: Insulin Pen Needle
Needle Bending in BD Nano™ PRO vs Each of 3 Comparator Pen Needles
-0.39 Difference in incidence
Interval -1.82 to 1.04
0.13 Difference in incidence
Interval -2.8 to 3.06
0.42 Difference in incidence
Interval -1.91 to 2.75

SECONDARY outcome

Timeframe: Leakage was measured directly after each injection

Population: Per protocol population

After saline delivery equivalent to 30U of U100 insulin (0.3mL) and subject removal of pen needle from body, study staff used the provided materials and scale to absorb leakage from the pen needle tip and injection site to measure the amount of leakage. Leakage over 0.015g was counted as an event. The incidence of leakage (yes/no) was calculated for each groups and the mean difference calculated along with a 95% confidence interval. A positive score indicates fewer leakage events with the BD Nano™ PRO and a negative score indicates fewer leakage events with the competitor. Scores from each injection (308 for each needle type) were pooled and a mean was calculated. The incidence of needle leakage in the BD Nano™ PRO and each comparator were compared and the mean difference reported with a 95% confidence interval.

Outcome measures

Outcome measures
Measure
BD Nano™ PRO Pen Needle vs 34G Artsana Insupen Extr3me
n=308 Pen Needles
Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2 BD Nano™ PRO: Insulin Pen needle 34G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs 33G Artsana Insupen Extr3me
n=308 Pen Needles
Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle 33G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs Simple Diagnostics Comfort EZ™
n=308 Pen Needles
Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle Simple Diagnostics Comfort EZ™: Insulin Pen Needle
Superiority of BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Leakage)
-5.70 Difference in incidence
Interval -9.0 to -3.5
-14.09 Difference in incidence
Interval -26.49 to -1.69
-0.20 Difference in incidence
Interval -1.9 to 0.6

SECONDARY outcome

Timeframe: Immediately after injection Pair

Population: Subjects protocol population with non-missing data

Subject perceived force required to deliver dose; measured by a relative 5 point Likert scale. The scale ranged from -2 to 2, where positive scores indicated less thumb force required for the BD Nano™ PRO, and negative scores indicated less thumb force for the comparator. Scores from each of the paired injections were pooled and a mean was calculated.

Outcome measures

Outcome measures
Measure
BD Nano™ PRO Pen Needle vs 34G Artsana Insupen Extr3me
n=306 paired injections
Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2 BD Nano™ PRO: Insulin Pen needle 34G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs 33G Artsana Insupen Extr3me
n=305 paired injections
Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle 33G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs Simple Diagnostics Comfort EZ™
n=307 paired injections
Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle Simple Diagnostics Comfort EZ™: Insulin Pen Needle
Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Force)
0.8 Score on a scale
Interval 0.62 to 0.98
1.0 Score on a scale
Interval 0.8 to 1.16
0.3 Score on a scale
Interval 0.13 to 0.49

OTHER_PRE_SPECIFIED outcome

Timeframe: Time of injection

Population: Per Protocol Population

Time from when subject when is depressed and time when removed from body.

Outcome measures

Outcome measures
Measure
BD Nano™ PRO Pen Needle vs 34G Artsana Insupen Extr3me
n=1848 Pen needles
Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2 BD Nano™ PRO: Insulin Pen needle 34G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs 33G Artsana Insupen Extr3me
Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle 33G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs Simple Diagnostics Comfort EZ™
Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle Simple Diagnostics Comfort EZ™: Insulin Pen Needle
Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Total Injection Time)
BD NANO
8.39 seconds
Standard Deviation 5.26
Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Total Injection Time)
Artsana 33G
10.98 seconds
Standard Deviation 2.64
Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Total Injection Time)
Arstana 34G
9.93 seconds
Standard Deviation 5.16
Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Total Injection Time)
Comfort EZ 33G
8.63 seconds
Standard Deviation 5.30

POST_HOC outcome

Timeframe: Immediately after injection

Population: Per Protocol Population

A needle was considered broken if the patient end and canula was separated into 2 pieces. The number and proportion of needle breaking occurrence for each pen needle type were summarized. The incidence of broken needle events for the BD Nano PRO was compared to each of the 3 comparator products and the mean difference reported with a 95% confidence interval.

Outcome measures

Outcome measures
Measure
BD Nano™ PRO Pen Needle vs 34G Artsana Insupen Extr3me
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2 BD Nano™ PRO: Insulin Pen needle 34G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs 33G Artsana Insupen Extr3me
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle 33G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs Simple Diagnostics Comfort EZ™
n=308 paired injections
Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle Simple Diagnostics Comfort EZ™: Insulin Pen Needle
Compare BD Nano™ PRO vs Each of 3 Comparator Pen Needles (Needle Breaking)
0 Difference in incidence
Interval -0.4 to 1.2
0 Difference in incidence
Interval -0.4 to 1.2
0 Difference in incidence
Interval -0.4 to 1.2

POST_HOC outcome

Timeframe: At the end of study

Population: Each subject was provided a 4 question survey of their general experience with pen needles. The questions were based on a a 5 point type of Likert scale.

Each subject was given a non-comparative 4-question survey on Pen needle characteristics.

Outcome measures

Outcome measures
Measure
BD Nano™ PRO Pen Needle vs 34G Artsana Insupen Extr3me
n=154 Participants
Subjects are to perform 2 pairs of injections. Each pair consists of Nano™ PRO pen needle vs Artsana Insupen Extr3me 3.5mm x 34G x 2 BD Nano™ PRO: Insulin Pen needle 34G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs 33G Artsana Insupen Extr3me
Subjects are to perform 2 pairs of injections. Each Pair consists of BD Nano™ PRO pen needle vs Artsana Insupen Extr3me 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle 33G Artsana Insupen Extr3me: Insulin Pen Needle
BD Nano™ PRO Pen Needle vs Simple Diagnostics Comfort EZ™
Subjects are to perform 2 pairs of injections. Each pair consists of BD Nano™ PRO pen needle vs Simple Diagnostics Comfort EZ™ 4mm x 33G x 2 BD Nano™ PRO: Insulin Pen needle Simple Diagnostics Comfort EZ™: Insulin Pen Needle
Subject Satisfaction Survey
Post injection leakage affects my level of concern · Somewhat Agree
31 Participants
Subject Satisfaction Survey
Post injection leakage affects my level of concern · Neutral
23 Participants
Subject Satisfaction Survey
Injection pain affects my level of satisfaction · Agree
56 Participants
Subject Satisfaction Survey
Injection pain affects my level of satisfaction · Somewhat Agree
46 Participants
Subject Satisfaction Survey
Injection pain affects my level of satisfaction · Neutral
27 Participants
Subject Satisfaction Survey
Injection pain affects my level of satisfaction · Somewhat disagree
8 Participants
Subject Satisfaction Survey
Injection pain affects my level of satisfaction · Disagree
17 Participants
Subject Satisfaction Survey
Thumb pressure affects my level of satisfaction · Agree
54 Participants
Subject Satisfaction Survey
Thumb pressure affects my level of satisfaction · Somewhat Agree
51 Participants
Subject Satisfaction Survey
Thumb pressure affects my level of satisfaction · Neutral
26 Participants
Subject Satisfaction Survey
Thumb pressure affects my level of satisfaction · Somewhat disagree
9 Participants
Subject Satisfaction Survey
Thumb pressure affects my level of satisfaction · Disagree
14 Participants
Subject Satisfaction Survey
Post injection leakage affects my level of concern · Agree
76 Participants
Subject Satisfaction Survey
Post injection leakage affects my level of concern · Somewhat disagree
8 Participants
Subject Satisfaction Survey
Post injection leakage affects my level of concern · Disagree
16 Participants
Subject Satisfaction Survey
A bend needle increases my level of concern · Agree
100 Participants
Subject Satisfaction Survey
A bend needle increases my level of concern · Somewhat Agree
28 Participants
Subject Satisfaction Survey
A bend needle increases my level of concern · Neutral
13 Participants
Subject Satisfaction Survey
A bend needle increases my level of concern · Somewhat disagree
2 Participants
Subject Satisfaction Survey
A bend needle increases my level of concern · Disagree
11 Participants

Adverse Events

BD Nano™ PRO Pen Needle

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

34G Artsana Insupen Extr3me

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

33G Artsana Insupen Extr3me

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Simple Diagnostics Comfort EZ™

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Michael Gibney

Becton Dickinson

Phone: 201-847-6170

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place